×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
OCS – oculis holding ag - ordinary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
OCS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/12
01:41 am
ocs
Oculis Holding (NasdaqGM:OCS) Valuation Check As Privosegtor Wins FDA Breakthrough Therapy Status [Yahoo! Finance]
Low
Report
Oculis Holding (NasdaqGM:OCS) Valuation Check As Privosegtor Wins FDA Breakthrough Therapy Status [Yahoo! Finance]
1/11
06:40 am
ocs
Why Oculis Holding (OCS) Is Up 15.3% After FDA Breakthrough Status For Privosegtor In Optic Neuritis [Yahoo! Finance]
Low
Report
Why Oculis Holding (OCS) Is Up 15.3% After FDA Breakthrough Status For Privosegtor In Optic Neuritis [Yahoo! Finance]
1/8
04:00 am
ocs
Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthalmology and Ophthalmology at the 2026 J.P. Morgan Healthcare Conference
Medium
Report
Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthalmology and Ophthalmology at the 2026 J.P. Morgan Healthcare Conference
1/6
04:23 am
ocs
Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis [Yahoo! Finance]
Medium
Report
Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis [Yahoo! Finance]
1/6
04:00 am
ocs
Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis
Medium
Report
Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis
12/19
10:09 am
ocs
Oculis (NASDAQ:OCS) had its price target raised by analysts at Stifel Nicolaus from $35.00 to $40.00. They now have a "buy" rating on the stock.
Low
Report
Oculis (NASDAQ:OCS) had its price target raised by analysts at Stifel Nicolaus from $35.00 to $40.00. They now have a "buy" rating on the stock.
12/19
08:04 am
ocs
Oculis (NASDAQ:OCS) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $38.00 price target on the stock.
Low
Report
Oculis (NASDAQ:OCS) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $38.00 price target on the stock.
12/3
09:05 am
ocs
Oculis (NASDAQ:OCS) is now covered by analysts at Lifesci Capital. They set an "outperform" rating and a $55.00 price target on the stock.
Low
Report
Oculis (NASDAQ:OCS) is now covered by analysts at Lifesci Capital. They set an "outperform" rating and a $55.00 price target on the stock.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/14
04:33 pm
ocs
Form SCHEDULE 13G/A Oculis Holding AG Filed by: Pivotal bioVenture Partners Fund I, L.P.
Low
Report
Form SCHEDULE 13G/A Oculis Holding AG Filed by: Pivotal bioVenture Partners Fund I, L.P.
11/10
04:07 pm
ocs
Form 6-K Oculis Holding AG For: Nov 10
Low
Report
Form 6-K Oculis Holding AG For: Nov 10
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: